{
  "primary": "Smad3",
  "interaction_type": "direct",
  "upstream_interactor": null,
  "mediator_chain": [],
  "depth": 1,
  "support_summary": "HDAC6 is required for the phosphorylation and nuclear accumulation of Smad3 in response to TGF-β1, playing a role in epithelial-mesenchymal transition (EMT).",
  "functions": [
    {
      "function": "TGF-beta Signaling Pathway",
      "arrow": "activates",
      "cellular_process": "HDAC6 is a cytoplasmic deacetylase that directly targets the transcription factor Smad3, a key mediator of TGF-β signaling. The acetylation state of Smad3 acts as a molecular switch controlling its activity.",
      "effect_description": "HDAC6-mediated deacetylation of Smad3 in the cytoplasm is a prerequisite for its subsequent phosphorylation at Ser423/425 upon TGF-β stimulation. This phosphorylation event triggers Smad3's nuclear translocation and activation of target gene transcription. Conversely, inhibition of HDAC6 leads to Smad3 hyperacetylation, which prevents its phosphorylation and thereby blocks the signaling cascade.",
      "biological_consequence": [
        "HDAC6 deacetylates cytoplasmic Smad3 → Deacetylated Smad3 is competent for phosphorylation upon TGF-β receptor activation → Smad3 is phosphorylated at Ser423/425 → Phosphorylated Smad3 translocates to the nucleus → Activation of fibrotic gene transcription → Promotion of fibrosis"
      ],
      "specific_effects": [
        "HDAC6 inhibition leads to an increase in Smad3 acetylation in the cytoplasm.",
        "Increased Smad3 acetylation prevents its phosphorylation in response to TGF-β stimulation.",
        "Pharmacological or genetic inhibition of HDAC6 completely blocks TGF-β1-induced Smad3 phosphorylation and subsequent nuclear translocation.",
        "By blocking the TGF-β/Smad3 pathway, HDAC6 inhibition reduces the expression of fibrotic genes and can ameliorate fibrosis in vivo."
      ],
      "evidence": [
        {
          "paper_title": "Pharmacological inhibition of HDAC6 improves muscle phenotypes in dystrophin-deficient mice by downregulating TGF-β via Smad3 acetylation",
          "journal": "Nature Communications",
          "year": 2022,
          "relevant_quote": "By increasing Smad3 acetylation in the cytoplasm, HDAC6 inhibition reduces Smad2/3 phosphorylation, nuclear translocation, and transcriptional activity. These findings provide in vivo evidence that Smad3 is a new target of HDAC6...",
          "pmid": "36402791"
        }
      ],
      "pathway": {
        "name": "TGF-beta Signaling Pathway",
        "canonical_name": "TGF-beta Signaling",
        "ontology_id": "hsa04350",
        "ontology_source": "KEGG",
        "confidence": 0.8
      },
      "pmids": [
        "36402791"
      ],
      "interaction_effect": "activates",
      "interaction_direction": "main_to_primary",
      "function_effect": "activation"
    }
  ],
  "arrow": "activates",
  "direction": "main_to_primary",
  "intent": "regulation",
  "arrows": {
    "main_to_primary": [
      "activates"
    ]
  },
  "is_valid": true,
  "mechanism_correction": null,
  "mechanism": "HDAC6 is a cytoplasmic deacetylase that directly targets the transcription factor Smad3, a key mediator of TGF-β signaling. The acetylation state of Smad3 acts as a molecular switch controlling its activity.",
  "effect": "HDAC6-mediated deacetylation of Smad3 in the cytoplasm is a prerequisite for its subsequent phosphorylation at Ser423/425 upon TGF-β stimulation. This phosphorylation event triggers Smad3's nuclear translocation and activation of target gene transcription. Conversely, inhibition of HDAC6 leads to Smad3 hyperacetylation, which prevents its phosphorylation and thereby blocks the signaling cascade.",
  "summary": "HDAC6 activates Smad3 to modulate tgf-beta signaling pathway, ultimately affecting promotion of fibrosis.",
  "evidence": [
    {
      "paper_title": "Pharmacological inhibition of HDAC6 improves muscle phenotypes in dystrophin-deficient mice by downregulating TGF-β via Smad3 acetylation",
      "journal": "Nature Communications",
      "year": 2022,
      "relevant_quote": "By increasing Smad3 acetylation in the cytoplasm, HDAC6 inhibition reduces Smad2/3 phosphorylation, nuclear translocation, and transcriptional activity. These findings provide in vivo evidence that Smad3 is a new target of HDAC6..."
    },
    {
      "paper_title": "Histone deacetylase 6 inhibition counteracts the epithelial–mesenchymal transition of peritoneal mesothelial cells and prevents peritoneal fibrosis",
      "journal": "Oncotarget",
      "year": 2017,
      "relevant_quote": "HDAC6 is required for activation of the TGF-β1/Smad3 signaling pathway in peritoneal mesothelial cells... At 20 μM, TA [Tubastatin A] completely blocked Smad-3 phosphorylation. Similarly, knocking down of HDAC6 by siRNA also resulted in a complete blockage of Smad3 phosphorylation in HPMCs exposed to TGF-β1."
    }
  ],
  "pathways": [
    {
      "name": "TGF-beta Signaling Pathway",
      "canonical_name": "TGF-beta Signaling",
      "ontology_id": "hsa04350",
      "ontology_source": "KEGG",
      "confidence": 0.8
    }
  ],
  "interaction_effect": "activation",
  "_validation_metadata": {
    "validated": true,
    "validator": "arrow_effect_validator",
    "corrections_applied": 1
  },
  "_arrow_validated": true,
  "arrow_notation": "HDAC6 --activates--> Smad3:",
  "protein_a": "HDAC6",
  "protein_b": "Smad3",
  "discovered_in_query": "HDAC6",
  "first_discovered": "2025-12-04T16:37:52.690822Z",
  "last_updated": "2025-12-04T16:37:52.690822Z"
}